Personalized treatment is highly desirable in multiple sclerosis (MS). We believe that multidisciplinary measurements including clinical, functional and patient-reported outcome measures in combination with extensive patient profiling can enhance personalized treatment and rehabilitation strategies. We elaborate on four reasons behind this statement: (1) MS disease activity and progression are complex and multidimensional concepts in nature and thereby defy a one-size-fits-all description, (2) functioning, progression, treatment, and rehabilitation effects are interdependent and should be investigated together, (3) personalized healthcare is based on the dynamics of system biology and on technology that confirms a patient’s fundamental biology and (4) inclusion of patient-reported outcome measures can facilitate patient-relevant healthcare. We discuss currently available multidisciplinary MS data initiatives and introduce joint actions to further increase the overall success. With this topical review, we hope to drive the MS community to invest in expanding towards more multidisciplinary and longitudinal data collection.
CadavidDTangYO’NeillG.Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol2010; 51: 321–329.
2.
NobleJGOsborneLAJonesKHet al. Commentary on ‘disability outcome measures in multiple sclerosis clinical trials’. Mult Scler2012; 18: 1718–1720.
3.
PolmanCHRudickRA.The multiple sclerosis functional composite: A clinically meaningful measure of disability. Neurology2010; 74(Suppl. 3): S8–S15.
4.
CadavidDCohenJAFreedmanMSet al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler2017; 23: 94–105.
5.
ProsperiniLPiattellaMCGianniCet al. Functional and structural brain plasticity enhanced by motor and cognitive rehabilitation in multiple sclerosis. Neural Plast2015; 2015: 481–574.
6.
FeysPMoumdjianLVan HalewyckFet al. Effects of an individual 12-week community-located ‘start-to-run’ program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis. Mult Scler2019; 25: 92–103.
7.
SandroffBMMotlRWScudderMRet al. Systematic, evidence-based review of exercise, physical activity, and physical fitness effects on cognition in persons with multiple sclerosis. Neuropsychol Rev2016; 26: 271–294.
8.
KhanFAmatyaB.Rehabilitation in multiple sclerosis: A systematic review of systematic reviews. Arch Phys Med Rehabil2017; 98: 353–367.
9.
GoveroverYChiaravallotiNDO’BrienAet al. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: An updated review of the literature from 2007 to 2016. Arch Phys Med Rehabil2017; 99: 390–407.
10.
RiemenschneiderMHvidLGStenagerEet al. Is there an overlooked ‘window of opportunity’ in MS exercise therapy? Perspectives for early MS rehabilitation. Mult Scler2018; 24: 886–894.
11.
MaritzRAronskyDProdingerB.The International Classification of Functioning, Disability and Health (ICF) in electronic health records. A systematic literature review. Appl Clin Inform2017; 8: 964–980.
12.
KarhulaMEKanelistoKJRuutiainenJet al. The activities and participation categories of the ICF Core Sets for multiple sclerosis from the patient perspective. Disabil Rehabil2013; 35: 492–497.
13.
LaroccaNG.Impact of walking impairment in multiple sclerosis: Perspectives of patients and care partners. Patient2011; 4: 189–201.
14.
ComabellaMMontalbanX.Body fluid biomarkers in multiple sclerosis. Lancet Neurol2014; 13: 113–126.
PeetersLMVanheusdenMSomersVet al. Cytotoxic CD4+ T cells drive multiple sclerosis progression. Front Immunol2017; 8: 1160.
17.
RieckmannPCentonzeDElovaaraIet al.;Members of the MS in the 21st Century Steering Group. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord2018; 19: 153–160.
18.
KallaurAPReicheEMOliveiraSRet al. Genetic, immune-inflammatory, and oxidative stress biomarkers as predictors for disability and disease progression in multiple sclerosis. Mol Neurobiol2017; 54: 31–44.
19.
FayersPMachinD.Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. Hoboken, NJ: John Wiley & Sons, 2013.
20.
Langeskov-ChristensenDFeysPBaertIet al. Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis. J Neurol Sci2017; 382: 131–136.
21.
ZiemssenTKempckeREulitzMet al. Multiple sclerosis documentation system (MSDS): Moving from documentation to management of MS patients. J Neural Transm2013; 120(Suppl. 1): S61–S66.
22.
KatzanISpeckMDoplerCet al. The Knowledge Program: An innovative, comprehensive electronic data capture system and warehouse. AMIA Annu Symp Proc2011; 2011: 683–692.
23.
GourraudPAHenryRGCreeBAet al. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol2014; 76: 633–642.
24.
BeboBFJrFoxRJLeeKet al. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Mult Scler2018; 24: 579–586.
25.
PeetersLM.Fair data for next-generation management of multiple sclerosis. Mult Scler2018; 24: 1151–1156.
26.
BradfordEHBaertIFinlaysonMet al. Feasibility of an international multiple sclerosis rehabilitation data repository: Perceived challenges and motivators for sharing data. Int J MS Care2018; 20: 17–26.
27.
ButzkuevenHChapmanJCristianoEet al. MSBase: An international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler2006; 12: 769–774.
28.
KalincikTManouchehriniaASobisekLet al. Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response. Brain2017; 140: 2426–2443.
29.
SorensenPGiovannoniGMontalbanXet al. The Multiple Sclerosis Care Unit. Mult Scler Epub ahead of print 23 October 2018. DOI: 10.1177/1352458518807082.
30.
BeckerWCEdmondSNCervoneDJet al. Evaluation of an integrated, multidisciplinary program to address unsafe use of opioids prescribed for pain. Pain Med2018; 19: 1419–1424.
31.
BoesenFNorgaardMTrenelPet al. Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: A pragmatic randomized controlled trial – The Danish MS Hospitals Rehabilitation Study. Mult Scler2018; 24: 340–349.
32.
Fernandez-NavarroPLopez-AbenteGSalido-CamposCet al. The Minimum Basic Data Set (MBDS) as a tool for cancer epidemiological surveillance. Eur J Intern Med2016; 34: 94–97.
33.
European Medicines Agency SMH. Initiative for patient registries: Strategy and pilot phase. Inspections and Human Medicines Pharmacovigilance Division, London, 15September2015.
34.
European Medicines Agency SMH. Report on multiple sclerosis registries – workshop 7 July 2017. Inspections, Human Medicines, Pharmacovigilance and committee Division, London, 9October2017.
35.
EngelhardMMPatekSDLachJCet al. Real-world walking in multiple sclerosis: Separating capacity from behavior. Gait Posture2018; 59: 211–216.
36.
FeysPLamersIFrancisGet al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler2017; 23: 711–720.
37.
MotlRWCohenJABenedictRet al. Validity of the Timed 25-Foot Walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler2017; 23: 704–710.
38.
BalcerLJRaynowskaJNolanRet al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler2017; 23: 734–747.
39.
FeysPGiovannoniGDijsselbloemNet al. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler2016; 22: 34–46.
40.
CurtisLHBrownJPlattR.Four health data networks illustrate the potential for a shared national multipurpose big-data network. Health Aff2014; 33: 1178–1186.
41.
FleurenceRLCurtisLHCaliffRMet al. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc2014; 21: 578–582.
42.
VaudanoEVannieuwenhuyseBVan Der GeytenSet al. Boosting translational research on Alzheimer’s disease in Europe: The Innovative Medicine Initiative AD research platform. Alzheimers Dement2015; 11: 1121–1122.
43.
Healthdata. La Collecte des données. Brussels: WIV-ISP, 2015.
